Viral Vector Manufacturing Services
The development and clinical translation of cell and gene therapies requires reliable viral vector production supported by robust manufacturing and analytical strategies. Our CDMO teams provide integrated expertise and established production platforms to support efficient viral vector development and manufacturing across the product lifecycle.
With multiple manufacturing frameworks and flexible production platforms, our viral vector center of excellence enables developers to select the most appropriate strategy for their specific therapeutic program. Our capabilities include integrated plasmid DNA production, vector development, and scalable manufacturing processes designed to support both early-stage research and GMP-compliant clinical supply.
From research-grade vector production and packaging services to fully customized GMP viral vector manufacturing, we provide comprehensive support to advance programs from early development through clinical and commercial manufacturing. Leveraging decades of experience in advanced therapy development, our teams work closely with therapeutic developers to streamline viral vector programs and facilitate efficient progression toward clinical application.
GMP AAV Vector Production
Adeno-associated virus (AAV) vectors are widely used for gene therapy applications requiring efficient and stable gene delivery. Our CDMO teams provide GMP-compliant AAV manufacturing services designed to support the progression of gene therapy programs from early development through clinical production.
Using the established nAAVigation® AAV manufacturing platform, we offer standardized and scalable production processes that support predictable development timelines and consistent vector quality. Our multidisciplinary teams combine process development, analytical characterization, and manufacturing expertise to help advance AAV programs efficiently toward clinical readiness
Custom CGMP Virus Production
Our CDMO teams provide custom cGMP virus production services for a broad range of viral platforms beyond commonly used gene therapy vectors such as AAV, adenovirus, and lentivirus. With extensive experience supporting vaccine development and other viral therapeutic programs, we offer flexible manufacturing solutions tailored to specific project requirements.
Production of infectious, replication-competent viruses is conducted within dedicated cGMP suites that are physically segregated from other viral vector manufacturing areas to ensure appropriate biosafety and containment. Our teams collaborate closely with developers to design and implement customized virus production strategies aligned with program objectives, regulatory expectations, and manufacturing requirements.
GMP Adenovirus Vector Production
Adenovirus-based gene therapy approaches, including oncolytic adenoviruses, continue to attract significant interest across the advanced therapy landscape. Our CDMO teams provide GMP-compliant adenovirus vector manufacturing services designed to support the progression of gene therapy programs from early development through clinical production.
Recognizing that no single production strategy is optimal for every program, we offer flexible adenovirus manufacturing workflows and provide technical guidance to help developers select the most appropriate process based on program requirements, scalability considerations, and regulatory expectations.
GMP Lentiviral Vector Production
Lentiviral vectors play a critical role in the development of many cell and gene therapies by enabling stable genetic modification of target cells. As clinical programs involving CAR-T therapies and other ex vivo gene therapy approaches continue to expand, the demand for reliable GMP-grade lentiviral vector production has increased accordingly.
Our CDMO teams leverage the lentiviral vector manufacturing platform alongside decades of experience in viral vector production to support scalable and reproducible lentivirus manufacturing. These capabilities address key development challenges including process scalability, product quality, regulatory compliance, and vector stability, enabling efficient progression from early development through clinical manufacturing.
GMP Retroviral Vector Production
Retroviral vectors remain an important platform for gene and gene-modified cell therapy applications, including many CAR-T development programs. As the number and diversity of clinical trials in the cell and gene therapy field continues to expand, the demand for reliable GMP-grade retroviral vector manufacturing has increased accordingly.
Our CDMO teams provide established retroviral vector production capabilities designed to support programs from early development through clinical and commercial manufacturing. With multiple manufacturing strategies available, we offer flexible process options and technical expertise to help developers select the most appropriate production approach based on program requirements, scalability considerations, and regulatory expectations.
Actcell Labs Inc
1361 Amsterdam Ave.,
Floor 3, New York,
NY 10027, USA
+1 888 4880155
support@actcelllabs.com